These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 38579097)
1. Comparison of sacubitril/valsartan with olmesartan for hypertension: A meta-analysis of randomized controlled trials. Sun Y; Yang H Medicine (Baltimore); 2024 Apr; 103(14):e37501. PubMed ID: 38579097 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Comparative of Sacubitril/Valsartan vs. Olmesartan in the Treatment of hypertension: A Meta-analysis of RCTs. Han Y; Zhou Y; Na J; Li F; Sun Y Am J Hypertens; 2023 Nov; 36(12):643-650. PubMed ID: 37596996 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared With Olmesartan in Elderly Asian Patients (≥65 Years) With Systolic Hypertension. Supasyndh O; Wang J; Hafeez K; Zhang Y; Zhang J; Rakugi H Am J Hypertens; 2017 Nov; 30(12):1163-1169. PubMed ID: 28992296 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study. Huo Y; Li W; Webb R; Zhao L; Wang Q; Guo W J Clin Hypertens (Greenwich); 2019 Jan; 21(1):67-76. PubMed ID: 30536595 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials. Wu HX; Liu KK; Li BN; Liu S; Jin JC Ann Palliat Med; 2022 May; 11(5):1811-1825. PubMed ID: 35672897 [TBL] [Abstract][Full Text] [Related]
6. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study. Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087 [TBL] [Abstract][Full Text] [Related]
7. Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis. Almarjan AI; Almarjan SA; Masoud AT High Blood Press Cardiovasc Prev; 2023 May; 30(3):207-218. PubMed ID: 37017901 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study. Cheung DG; Aizenberg D; Gorbunov V; Hafeez K; Chen CW; Zhang J J Clin Hypertens (Greenwich); 2018 Jan; 20(1):150-158. PubMed ID: 29338113 [TBL] [Abstract][Full Text] [Related]
9. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study. Williams B; Cockcroft JR; Kario K; Zappe DH; Brunel PC; Wang Q; Guo W Hypertension; 2017 Mar; 69(3):411-420. PubMed ID: 28093466 [TBL] [Abstract][Full Text] [Related]
10. Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials. Geng Q; Yan R; Wang Z; Hou F Cardiology; 2020; 145(9):589-598. PubMed ID: 32726791 [TBL] [Abstract][Full Text] [Related]
11. Antihypertensive effect of sacubitril/valsartan: a meta-analysis. De Vecchis R; Ariano C; Soreca S Minerva Cardioangiol; 2019 Jun; 67(3):214-222. PubMed ID: 30895762 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension. Wang X; Song F; Jiang L; Huang Z; Luo S; Li X; He X Am J Hypertens; 2024 Jul; 37(8):612-620. PubMed ID: 38564196 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Rakugi H; Kario K; Yamaguchi M; Sasajima T; Gotou H; Zhang J Hypertens Res; 2022 May; 45(5):824-833. PubMed ID: 35058583 [TBL] [Abstract][Full Text] [Related]
14. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis. Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046 [TBL] [Abstract][Full Text] [Related]
15. Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study. Kario K; Rakugi H; Yarimizu D; Morita Y; Eguchi S; Iekushi K J Am Heart Assoc; 2023 Apr; 12(8):e027612. PubMed ID: 37026551 [TBL] [Abstract][Full Text] [Related]
16. Network meta-analysis of sacubitril/valsartan for the treatment of essential hypertension. Zhang Y; Zhao X; Huang H; Li M Clin Res Cardiol; 2023 Jul; 112(7):855-867. PubMed ID: 36326841 [TBL] [Abstract][Full Text] [Related]
17. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Jackson AM; Jhund PS; Anand IS; Düngen HD; Lam CSP; Lefkowitz MP; Linssen G; Lund LH; Maggioni AP; Pfeffer MA; Rouleau JL; Saraiva JFK; Senni M; Vardeny O; Wijkman MO; Yilmaz MB; Saito Y; Zile MR; Solomon SD; McMurray JJV Eur Heart J; 2021 Sep; 42(36):3741-3752. PubMed ID: 34392331 [TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis. Zhou W; Yang X; Jin J; Cheng M; Li Y; Bai Y; Xu J Int Urol Nephrol; 2024 Jan; 56(1):181-190. PubMed ID: 37195574 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant article. Lin J; Zhou J; Xie G; Liu J Medicine (Baltimore); 2021 Dec; 100(52):e28231. PubMed ID: 34967357 [TBL] [Abstract][Full Text] [Related]
20. Treatment with Sacubitril/Valsartan Effectively Manages Hypertension and Ameliorates Left Ventricular Hypertrophy in Hemodialysis Patients. Hu N; Lv N; Chen Y Blood Purif; 2024; 53(8):657-664. PubMed ID: 38824921 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]